Year: 2025
Type: article
Abstract: Immunotherapies for acute myeloid leukemia (AML) and other cancers are limited by a lack of tumor-specific targets. Here we discover that RNA-binding proteins and glycosylated RNAs (glycoRNAs) form precisely organized nanodomains on cancer cell surfaces. We characterize nucleophosmin (NPM1) as an abundant cell surface protein (csNPM1) on a variety of tumor types. With a focus on AML, we observe csNPM1 on blasts and leukemic stem cells but not on normal hematopoietic stem cells. We develop a monoclonal antibody to target csNPM1, which exhibits robust anti-tumor activity in multiple syngeneic and xenograft models of AML, including patient-derived xenografts, without observable toxicity. We find that csNPM1 is expressed in a mutation-agnostic manner on primary AML cells and may therefore offer a general strategy for detecting and treating AML. Surface profiling and in vivo work also demonstrate csNPM1 as a target on solid tumors. Our data suggest that csNPM1 and its neighboring glycoRNA-cell surface RNA-binding protein (csRBP) clusters may serve as an alternative antigen class for therapeutic targeting or cell identification.
Source: Nature Biotechnology
Authors: Benson M. George, Maria Eleftheriou, Eliza Yankova, Jonathan Perr, Peiyuan Chai, Gianluca Nestola, Karim Almahayni, Siân Evans, Aristi Damaskou, Helena Hemberger, Charlotta G. Lebedenko, Justyna Rak, Qi Yu, Ece Bapcum, James Russell, Jaana Bagri, Regan F. Volk, Malte Spiekermann, Richard M. Stone, George Giotopoulos, Brian J. P. Huntly, Joanna Baxter, Fernando Camargo, Jie Liu, Balyn W. Zaro, George S. Vassiliou, Leonhard Möckl, Jorge de la Rosa, Ryan A. Flynn, Konstantinos Tzelepis
Institutions: Boston Children's Hospital, Dana-Farber Cancer Institute, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Friedrich-Alexander-Universität Erlangen-Nürnberg, Max Planck Institute for the Science of Light, University of California, San Francisco, Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Altos Labs, Harvard University, Harvard Stem Cell Institute, Wellcome Sanger Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $12,690
Funders: Burroughs Wellcome Fund, Damon Runyon Cancer Research Foundation, National Philanthropic Trust, Sontag Foundation, Dana-Farber Cancer Institute, Wellcome Trust, UK Research and Innovation, Leukaemia UK, Cancer Research UK, National Institute for Health and Care Research, Department of Health and Social Care, Max-Planck-Gesellschaft, Medical Research Council, NIHR Cambridge Biomedical Research Centre, National Heart, Lung, and Blood Institute
Awards: G139696651, G1533125816, G1960665002, Cambridge Stem Cell Institute, G2834502797, G299057155, G3548141514, G370598735, Understanding the role of RNA modifications in myeloid leukaemogenesis, G4298573125, Molecular regulation of native hematopoiesis, Wellcome Four Year PhD Programme in Stem Cell Biology and Medicine, G5167026323, G5197108848, G5213524516, G6235975807, Cambridge Stem Cell Institute, G7864755017, G827207716, Cambridge Stem Cell Institute, The differential role of PU.1 in normal and malignant haematopoiesis: from master regulator of differentiation to coordinator of leukaemia networks
OpenAlex ID: W4409704822
